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The REDUCE-IT trial demonstrated that icosapent ethyl, an ethyl ester of eicosapen-
taenoic acid (EPA), reduced cardiovascular events in an at-risk population by a sub-
stantial degree. While the cardiovascular protective properties of this compound are
now proven, several other potential uses are being actively explored in clinical stud-
ies. These areas of investigation include cancer, inflammatory bowel disease, infec-
tions, Alzheimer’s disease, dementia, and depression. The next decade promises to
deepen our understanding of the beneficial effects that EPA may offer beyond car-
diovascular risk reduction.
Introduction
The data supporting use of the prescription medication ico-
sapent ethyl in patients similar to those enrolled in the
Reduction of Cardiovascular Events with Icosapent Ethyl -
Intervention Trial (REDUCE-IT) are robust.1–8 Several regis-
try analyses have found that these results may be
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applicable to a large proportion of patients with estab-
lished atherosclerosis involving any arterial bed or with dia-
betes mellitus.9–11 Analyses from REDUCE-IT support that
the primary mode of cardiovascular benefit is mediated
through high blood eicosapentaenoic acid (EPA) levels,
with basic science experiments ongoing to delineate the
exact downstream molecular mechanisms.12 REDUCE-IT in-
cluded 10% of patients with normal triglycerides.1,13,14
This subgroup had a similar relative risk reduction as
patients with higher triglyceride levels. Some physicians
will feel comfortable extrapolating from the current data
to these patient subsets even absent further large-scale
clinical trial testing—especially in higher risk patients.
Remaining questions in the cardiovascular space include
whether higher loading doses might provide incremental
value in acute settings, such as at the time of myocardial
infarction, ischaemic stroke, or revascularization. Patients
with a history of such events have already been shown to
have significant benefit from treatment with icosapent
ethyl in REDUCE-IT, but might they derive even greater
benefit if the drug had been administered at the time of
the event? The observation from a prespecified analysis of
REDUCE-IT showed that higher levels of on-treatment EPA
were highly correlated with lower rates of new heart fail-
ure, providing potential support for higher maintenance
doses of icosapent ethyl.12 Furthermore, studies are war-
ranted to see if icosapent ethyl could be used specifically
to reduce first or recurrent heart failure.15 Thus, there is a
pressing need for further research of EPA in cardiovascular
medicine. Perhaps even more intriguing is the potential
utility of EPA in other disease states.
Although the exact mechanisms of action of EPA in reduc-
ing cardiovascular events are not fully known, they are
likely multifactorial. The lipid effects of EPA may include
increased plasma lipoprotein lipase activity and decreased
lipogenesis in the liver.16 The non-lipid effects may include
anti-inflammatory properties, anti-oxidant effects, arte-
rial plaque modification and regression, anti-thrombotic
and anti-platelet effects, cell membrane stabilization, and
enhanced endothelial function.17,18 The central theme fig-
ure captures the potential mechanisms of action for the en-
suing discussions in this article (Figure). These mechanisms
need to be investigated further in ongoing and future clini-
cal trials.
Potential gastrointestinal applications of
eicosapentaenoic acid
Laboratory data support a potential benefit of EPA for the
reduction of colorectal cancer (CRC) risk.19 In a small ran-
domized placebo-controlled trial (RCT) of 55 patients with
familial adenomatous polyposis, an inherited CRC predis-
position syndrome, it was demonstrated that supplementa-
tion with EPA 2 g daily for 6months reduced the number
and size of adenomatous rectal polyps (the benign precur-
sor of the majority of ‘sporadic’ CRCs) by 20–30%.20 These
findings led to a phase III RCT, the seAFOod Polyp
Figure Ongoing Research on Icosapent Ethyl Outside of Cardiovascular Prevention. CRC, colorectal cancer; IBD, inflammatory bowel disease; IPE, icosa-
pent ethyl; SPMs, specialized pro-resolving mediators.
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Prevention Trial, which tested the effect of the same dose
of EPA in individuals with ‘sporadic’ colorectal adenoma-
tous polyps detected at colonoscopy in the English Bowel
Cancer Screening Programme (BCSP).21 Although the inter-
vention did not reduce the primary endpoint of the number
of individuals with one or more adenomatous polyps, a sta-
tistically significant reduction was observed in the second-
ary outcome of the number of adenomatous polyps,
particularly those in the left colon, an endpoint that is
more relevant to contemporary trials conducted in quality-
assured colonoscopy programmes, such as the English BCSP.
To examine the potential of EPA for primary prevention of
CRC, a prespecified ancillary study of colonoscopy out-
comes was carried out in the large phase III Vitamin D and
Omega-3 Trial (VITAL) of 25871 US adults free of cancer
and cardiovascular disease at enrolment.22 After treat-
ment with omega-3 fatty acids at a dose of 1 g daily [includ-
ing 460mg EPA and 380mg docosahexaenoic acid (DHA)]
for a median of 5.3 years, there was no difference in the
risk of either adenomatous or serrated polyps (the other
major precursor of CRC). Interestingly, a lower risk of ade-
nomatous polyps was reported in the omega-3 fatty acid
group compared with those assigned to placebo among
individuals with low plasma levels of omega-3 fatty acids at
baseline. A beneficial association of omega-3 fatty acid
supplementation was also observed in African-Americans,
but not in other racial/ethnic groups. These hypothesis-
generating findings of a potential preventive effect of a
low dose of omega-3 fatty acids in individuals with low
omega-3 fatty acid status or African-American persons
need to be validated in future large RCTs.
In addition to potential reduction in CRC risk, recent
data support benefit of high marine omega-3 fatty acid in-
take for survival of patients with established CRC. In a
Phase II RCTof EPA 2 g daily in 88 patients undergoing liver
resection for CRC liver metastasis, EPA treatment in-
creased overall and disease-free survival and reduced the
vascularity score of metastatic tumours compared with
placebo.23 Similar beneficial associations between high
EPA intake after CRC diagnosis and improved survival have
been reported in observational studies.24,25 Based on these
data, a larger-scale, placebo-controlled phase III RCT [EPA
for Metastasis Trial 2 (EMT2), NCT03428477] of treatment
with EPA (4g icosapent ethyl daily) was launched in the UK
for patients undergoing liver resection for CRC liver metas-
tasis. The findings of EMT2 are expected to become avail-
able in 2023 and will shed light on the potential of
integrating adjuvant EPA therapy into management of CRC
patients.
In contrast to oral supplementation, two intravenous
infusions of mixed omega-3 fatty acids at a dose of 0.2 g/
kg/day before and after surgery did not change serum lev-
els of inflammatory markers and, unexpectedly, resulted in
more infectious post-operative complications in a recent
RCT involving patients undergoing elective surgical resec-
tion for primary CRC.26
The anti-inflammatory properties of EPA have been in-
vestigated in the context of inflammatory bowel disease
(IBD). An initial report that EPA reduced relapse risk in
Crohn’s disease27 has not been replicated by other RCTs
and systematic reviews that suggest no overall benefit
from omega-3 fatty acids for the clinical course of Crohn’s
disease or ulcerative colitis (UC).28 However, observational
studies continue to link omega-3 fatty acid intake and
blood levels with reduced IBD risk,29 and a recent RCTcon-
cluded that EPA therapy reduced faecal calprotectin levels
in UC patients.30 Further studies of the precision use of EPA
for IBD prevention and treatment in defined circumstances
(e.g. maintenance of remission in UC) are warranted.
One mechanism that might explain possible anti-cancer
and anti-inflammatory effects of EPA in the gastrointestinal
tract is modulation of the gut microbiome.31 There is evi-
dence that EPA and other omega-3 fatty acids are associ-
ated with an increased number of immunomodulatory
bacteria, such as Lactobacillus and Bifidobacterium, and
short-chain fatty acid-producing bacteria.32 In support of
the relevance of these microbiome associations with CRC
and IBD,many of the EPA-enriched bacteria are found to be
depleted in CRC and IBD (e.g. short-chain fatty acid-
producing bacteria),33 whereas the bacteria reduced by
EPA may promote CRC (e.g. Fusobacterium nucleatum).34–
39 Eicosapentaenoic acid may also modify gut environmen-
tal conditions and change the composition of microbes.40–
44 Ongoing clinical trials are investigating the effect of EPA
on modulation of the intricate relationship between the
gut microbiome and tumour immunity (e.g. NCT03661047,
NCT03428477, and NCT04216251).
Eicosapentaenoic acid and infectious disease
Infectious diseases (lower respiratory tract infection, diar-
rheal diseases, tuberculosis, malaria, and human immuno-
deficiency virus, among others) are the leading causes of
mortality in low-income countries.45 Bacterial strains resis-
tant to antibiotics continue to arise secondary to spontane-
ous mutations and antibiotic over-utilization.46 The
ongoing global pandemic of severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) or coronavirus disease
2019 (COVID-19) brought renewed concern and focus to
humanity’s vulnerability to the rapid, widespread transmis-
sion of a dangerous virus against which we have neither
vaccine nor treatment.47 Sepsis continues to pose formida-
ble challenges both in terms of understanding its underly-
ing pathophysiology and instituting effective treatment.48
Identifying novel approaches to the treatment of infectious
diseases remains a major focus of scientific and clinical in-
quiry worldwide.
Polyunsaturated fatty acids (PUFAs) may exert beneficial
effects in the setting of infection.49 The antibacterial
effects of fatty acids were first recognized in the 1880s by
Koch.50 It was reported that the skin microbiome is kept in
check by PUFAs produced in dermal layers.51 The PUFAs ex-
ert a complex range of effects that impact bacterial viabil-
ity and control the intensity of the inflammatory response
induced by cellular constituents of the immune system.
The omega-3 fatty acid EPA has drawn particular attention
in these respects.
Membrane effects of eicosapentaenoic acid
Eicosapentaenoic acid is esterified to phospholipids (princi-
pally phosphatidylcholine and phosphatidylethanolamine
at the sn-2 site) in the lipid rafts of cell and bacterial
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membranes.52 A broad range of gram-positive (e.g.
Bacillus subtilis, Listeria monocytogenes, Staphylococcus
aureus) and gram-negative (e.g. Escherichia coli,
Helicobacter pylori, Pseudomonas aeruginosa) bacteria,
mycobacteria, and cyanobacteria were reported to be sus-
ceptible to the growth-inhibiting and cidal effects of EPA
when studied in vitro.53,54 Eicosapentaenoic acid induces
pathogen injury by altering the fluidity of bacterial mem-
branes and disrupting the cell wall and cell membrane.55
This results in transmembrane ion and metabolite leaks,
alterations in the interactions among membrane proteins,
impaired enzyme activity, loss in nutrient uptake capacity,
cell lysis, and inability to engage in electron transport and
oxidative phosphorylation, among other effects.56–59 There
are no human clinical trials which have evaluated the effi-
cacy of EPA in the setting of active infection independent
of antibiotic therapy.60 Polyunsaturated fatty acids may
also inhibit the replication of enveloped viruses.61
Eicosapentaenoic acid has been reported to inhibit the rep-
lication of the hepatitis C virus, an example of an envel-
oped virus.62 Because COVID-19 and other SARS-associated
coronaviruses are enveloped, it has been suggested that
omega-3 fatty acids be tested to resolve infection more
quickly and prevent cytokine storm syndrome.63,64 A num-
ber of trials are actively enrolling subjects with COVID-19,
or at high risk of infection, to determine the effect of EPA,
if any, in preventing infection with SARS-CoV-2 or mitigat-
ing inflammatory disease sequelae.65–68
Specialized pro-resolving molecules
Cytokine storm syndrome (CSS) is systemic inflammatory
response that can be precipitated, for example, by viral in-
fection [COVID-19, Middle East respiratory syndrome coro-
navirus (MERS), influenza] and gram-negative sepsis.69
Cytokine storm syndrome is a manifestation of a hyperacti-
vated immune system. In the setting of infection, it is cru-
cial that the immune and inflammatory responses be
activated in a way that efficiently clears infection without
incurring tissue destruction and death of the host.
Therapeutic efforts to attenuate inflammation and re-
duce risk for CSS events are extraordinarily challenging.
Inflammation is a critical component of host defence.
Finding a balance between controlling inflammation with-
out compromising the capacity to fight infection is no sim-
ple physiological matter. Molecular signalling pathways
that could resolve the inflammatory response in CSS are in-
appropriately inhibited. Under normal conditions, once in-
fection and injured tissue are cleared, intrinsic safety
mechanisms to resolve inflammation are activated. This is
mediated by specialized pro-resolving mediators (SPMs) of
inflammation.
Specialized pro-resolving mediators (also called immu-
noresolvents) are formed from arachidonic acid as well as
EPA, docosapentaenoic acid, and DHA. These PUFAs are lib-
erated from cell membrane phospholipids and are precur-
sors to the maresins, protectins, resolvins, and lipoxins, all
of which are SPMs and participate in the resolution of in-
flammation. The SPMs bind to highly specific surface recep-
tors on target cells.70
A variety of models suggest that EPA beneficially impacts
inflammatory tone through SPMs and other mechanisms.
The E series resolvins are downstream metabolites of
EPA. RvE1 inhibits cytokine production, reduces leucocyte
infiltration, promotes both neutrophil apoptosis and mac-
rophage phagocytic activity to clear cellular and inflamma-
tory debris (i.e. efferocytosis) and is a more potent anti-
inflammatory agent than aspirin or dexamethasone.71,72
RvE2 also inhibits neutrophil infiltration and induces potent
anti-inflammatory activity.73 Both RvE1 and RvE2 stimulate
IL-10 production.74 In an experimental murine model of as-
piration pneumonia, the infusion of RvE1 reduced intrapul-
monary levels of numerous interleukins and cytokines,
increased bacterial clearance, reduced neutrophil infiltra-
tion, and increased survival.75 The therapeutic utility of
RvE1 is being evaluated in a variety of scenarios, including
infection and inflammatory diseases.
Eicosapentaenoic acid and its downstream metabolites,
the E series resolvins, may offer novel approaches to the
treatment and/or prevention of infection and cytokine
storm that need to be further investigated in large, well-
controlled clinical trials.
Potential uses of eicosapentaenoic acid in
Alzheimer’s disease, dementia, and depression
Alzheimer’s disease and dementia
Dementia due to Alzheimer’s disease (AD) is a devastating
illness leading to progressive neurodegenerative changes
and cognitive decline. In 2019, there were roughly 50 mil-
lion people living with dementia worldwide.76 The number
of people living with dementia due to AD is expected to tri-
ple by 2050.76 Alzheimer’s disease is characterized by a
chronic, progressive neurodegeneration resulting from the
accumulation of fibrillary proteins in the form of beta-amy-
loid (Ab) plaques and hyperphosphorylated tau tangles.77
Overaccumulation of these substances leads to dysfunction
of synapses and neuronal loss.78 Importantly, these neuro-
degenerative changes begin decades before clinically ap-
parent disease.79,80 The National Institute on Aging (NIA)-
Alzheimer’s Association developed research criteria for de-
fining the asymptomatic or preclinical stages of AD as well
as progression to mild cognitive impairment (MCI) and AD81
based on in vivo measures of beta-amyloid and hyerphos-
phorylated tau and neurodegeneration, along with metrics
of cognitive ability. Despite their centrality to clinical AD,
the cause of dysregulation of beta-amyloid and tau pro-
teins, and subsequent onset of dementia, is poorly under-
stood. Likewise, not everyone who has AD pathology
develops symptoms of dementia. A number of other factors
from genetics to lifestyle to environmental exposures are
likely to influence the onset and course of AD.82–85
Indeed, AD often coexists with vascular dementia, which
is the second most common cause of dementia after
AD.86,87 Even in the absence of diagnosable vascular de-
mentia, cerebrovascular pathology can be a major risk fac-
tor for clinically diagnosed AD and cognitive decline.88 One
post-mortem pathology study found that cerebrovascular
disease was evident in 80% of people diagnosed with AD.89
Vascular risk factors, such as reduced regional cerebral
blood flow in areas of the brain related to memory and
Beyond cardiovascular medicine J57
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartjsupp/article/22/Supplem
ent_J/J54/5918444 by guest on 02 N
ovem
ber 2020
learning90 and arterial stiffness,91 are related to deficits in
cognitive ability. Other cardiovascular risk factors, such as
smoking, hypertension, diabetes, hypercholesterolaemia,
and elevated body mass index, have been associated
with markers of dementia risk, such as lower grey matter
volume and reduced white matter integrity.92
Cerebrovascular dysfunctionmay be part of the pathophys-
iology of AD or these risk factors may lower the threshold
at which AD pathology burden leads to observable symp-
toms of dementia.93,94 More than likely, vascular dysfunc-
tion acts synergistically with neurodegenerative changes
and leads to cognitive impairment.93
Like beta-amyloid and hyperphosphorylated tau accu-
mulation, cerebral dysfunction occurs early in the develop-
ment of AD pathology and decades before symptoms begin.
Yet, the effects of treating such early vascular dysfunction
in the brain are poorly understood. There is some evidence
that therapeutics which lower risk for vascular dysfunction,
such as antihypertensives, also lower the risk for MCI and
AD.95,96 Other cardiovascular risk factors, such as high cho-
lesterol levels, have been associated with MCI and AD
risk.97,98 However, the relationship between circulating
cholesterol and cholesterol in the brain is complex, and
randomized clinical trials of statins have generally failed to
show any therapeutic benefit on cognitive dysfunction.99
Another potential target for therapeutics are triglycerides
and triglyceride-rich lipoproteins. The brain is a
cholesterol-rich organ and enzymes involved in lipid trans-
port or metabolism have been linked to risk for AD.100 The
e4 variant of the Apolipoprotein E gene, for example, has
long been known to increase risk for AD.101 Apolipoprotein
E plays a role in the catabolism of triglyceride-rich lipopro-
teins. Another enzyme, lipoprotein lipase, which is critical
to the metabolism of triglyceride-rich lipoproteins, is re-
lated to both AD pathology and to cardiovascular risk fac-
tors and hypertriglyceridaemia.102,103
Eicosapentaenoic acid may improve arterial function
and cerebral blood flow, attenuating adverse brain changes
related to b-amyloid protein, and improving cognition in
animals—changes that need to be investigated for protec-
tion against AD.104–107 This agent is readily available for use
and has a good safety profile, making it a favourable agent
to consider for AD prevention. Currently, Carlsson et al. are
conducting a small randomized clinical trial to determine if
EPA beneficially affects cerebrovascular function or cogni-
tive performance in cognitively healthy adults at increased
risk for AD called Brain Amyloid and Vascular Effects of
Eicosapentaenoic Acid (BRAVE-EPA) (NCT02719327).108
Depression and n-3 polyunsaturated fatty acids:
spotlight on eicosapentaenoic acid
Cardiovascular disease and depression represent the two
most common causes of disability in high-income countries,
and it has been argued that a recurrent depressed mood
may be the ‘most important driver of overall quality of
life’.109 Nutritional factors, such as dietary consumption of
omega-3 and omega-6 PUFAs, for which amarked reduction
in the ratio of omega-3/omega-6 PUFAs has been observed
in recent decades,110 may constitute a relevant molecular
basis of depressive disorders.
Biological mechanisms implicated in depression
A number of biological mechanisms may be operative in de-
pression; these include effects on the autonomic nervous
system, platelet receptors and function, coagulation fac-
tors, proinflammatory cytokine production, endothelial
function, and neurohormonal factors; a role for genetic
factors, potentially involving variants in key genes of neu-
rotransmitter transport, such as that for serotonin, cannot
be excluded. Consequently, drugs which increase mono-
amine availability, and notably serotonin, represent key
therapeutics in major depression. However, many patients
respond partially or become refractory to treatment by
monoamines as shown in the VAST-D randomized clinical
trial, and therefore novel therapeutic approaches are
warranted.111
Clinical relevance of omega-3 polyunsaturated
fatty acids to treatment of depression
Over the period of the past 5 years, evidence has suggested
a potential role for EPA in treatment of depression. The
meta-analyses of Sarris et al.112 and of Hallahan et al.113
were instrumental in providing experimental evidence for
the potential benefits of omega-3 PUFAs when adminis-
tered as dietary supplements to patients with depression.
These analyses revealed that the symptoms of depression
were attenuated by consumption of omega-3 PUFA dietary
supplements. The analysis of Sarris et al.112 showedmoder-
ate benefit of EPA-predominant PUFA preparations as an
adjunct to conventional anti-depressant therapy in
patients with diagnosed depression. However, the study of
Hallahan et al.,113 which included 35 randomized,
placebo-controlled intervention trials, indicated that DHA-
predominant omega-3 PUFAs did not improve depression
symptoms relative to placebo, whereas EPA-predominant
preparations (>50% EPA) did. Overall, these findings are
consistent with those reported in an RCT, which showed
that EPA (as an adjuvant to maintenance medication)
exerted greater efficacy compared with DHA or placebo in
attenuation ofmild-to-moderate depression.114
Transport and metabolism of eicosapentaenoic
acid
Although EPA is synthesized primarily in the liver by enzy-
matic elongation and desaturation of precursors, such as a-
linolenic acid (ALA), it is the exogenous dietary route which
most effectively results in increase in circulating EPA con-
centrations.115 Circulating EPA occurs primarily in esteri-
fied form in the phospholipids, cholesteryl esters, and
triglycerides of plasma lipoproteins, (up to  40 nmol/mL
plasma), with minor amounts bound to plasma proteins
(<1 nmol/mL).116,117 It is the latter form which is readily
available for uptake by cells and tissues, and indeed in
which EPA may be transported into the brain.115 Absolute
tissue levels of EPA in brain are several-fold lower than
those of both ALA and DHA (<25nmol/g as compared to
10000nmol/g for the latter). The explanation appears to
reside in the short half-life and rapid metabolism of EPA in
brain tissue, part of which occurs by b-oxidation.115
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Brain metabolism of eicosapentaenoic acid: role
of microglial cells
By which mechanisms might EPA lead to attenuation of the
symptoms of depression? A critical element appears to in-
volve brain microglial cells, which preferentially esterify
EPA, leading to intracellular EPA concentrations which are
two-fold or more higher than those of DHA; this ratio can
be compared with an inverse ratio corresponding to an
100-fold excess of DHA to EPA in whole brain.115
Microglial cells are found throughout the brain and spinal
cord, representing 10–15% of all nervous tissue cells.
Importantly, they represent the resident macrophages of
the central nervous system, and as such, are active
immuno-inflammatory cells.
Evidence in human subjects and in animal models indi-
cates that mood disorders may be associated with dysfunc-
tion of the innate and adaptive immune systems.118
Moreover, chronic inflammation appears to be a critical
factor in the formation and maintenance of major depres-
sion in some patients; indeed, depression manifests more
frequently in patients displaying chronic inflammatory dis-
ease states, such as type 2 diabetes, obesity, and rheuma-
toid arthritis.119 While the mechanisms which underlie
these disorders are complex, evidence is forthcoming that
proinflammatory cytokines and inflammatory lipid media-
tors may modify not only the metabolism of neurotransmit-
ters but also neurogenesis and neuroplasticity.119
Significantly, microglial cells are implicated in the produc-
tion of proinflammatory cytokines in response to peripheral
inflammation.120 In addition, post-mortem studies in
patients with depression have documented microglial acti-
vation in several regions of brain tissue, including the fron-
tal cortex.121 Considered together then, microglial-driven
inflammation appears to represent a key feature of chroni-
cally stressed brains, and as such, has been suggested to
lead to alteration in the plasticity of neuronal
synapses.122Microglial-driven inflammation in brain tissue
may therefore represent a key factor in the aetiology of
depression.123
It is well established that EPA, like DHA, exhibits a wide
range of biological activities, and that several of these are
particularly relevant to the pathophysiology of uncon-
trolled inflammation.74,124 The biology of these effects is
complex and may involve a direct action of the n-3 PUFA it-
self, such as regulation of gene expression, or an effect of
one of its multiple metabolites, among which are the resol-
vins, pro-resolving mediators of inflammation.74 For EPA
specifically, studies in preclinical models have demon-
strated both neuroprotective and anti-inflammatory
effects.115 Moreover, EPA and/or its metabolites have been
found to potently attenuate inflammation in microglial
cells, an effect which may be mediated by the down-
regulation of proinflammatory cytokine production.74
Beyond modulation of inflammation, EPA inhibits the
synthesis of prostaglandin E2, itself an inhibitor of presyn-
aptic serotonin release.125 In this context, it is pertinent
that low brain serotonin levels are intimately associated
with marked behavioural consequences typical of
depression.126
Therapeutic potential of eicosapentaenoic acid
in depression
Emerging evidence supports the hypothesis that dietary
EPA supplementation may alleviate symptoms of depres-
sion, and that such effects may be mediated through its
anti-inflammatory actions on microglial cells on the one
hand, and through indirect modulation of synaptic seroto-
nin levels on the other. Based on the available evidence, an
International Society for Nutritional Psychiatry Research
expert panel suggests that 1–2 g per day of EPA (net EPA
from EPA/DHA combinations) may be utilized as adjunctive
treatment for the potential treatment of major depressive
disorder.127 Given the importance of depression to public
health worldwide, the suggestion that a rigorously
designed, adequately powered RCT be undertaken to eval-
uate the efficacy of EPA in attenuating the symptoms of de-
pression is worthy of consideration.
Conclusion
In conclusion, beyond the established indications for icosa-
pent ethyl, there remain other important populations in
which to study this safe and well-tolerated drug. A role in
cancer is being actively investigated. A potential role in
combating COVID-19, supported by early, limited basic sci-
ence data, is being investigated in clinical trials. Other on-
going trials will also help to explore possible benefits in
gastrointestinal disorders, preclinical or early AD, demen-
tia, and the treatment of major depression as an adjunct
to antidepressants. These and other future trials will deter-
mine whether there will be a role for EPA-based therapy
outside of cardiovascularmedicine.
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